Filing Details
- Accession Number:
- 0000950170-24-015557
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-14 20:53:45
- Reporting Period:
- 2024-02-12
- Accepted Time:
- 2024-02-14 20:53:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1446847 | Ironwood Pharmaceuticals Inc | IRWD | Pharmaceutical Preparations (2834) | 043404176 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1808509 | Michael Shetzline | C/O Ironwood Pharmaceuticals, Inc. 100 Summer Street, Suite 2300 Boston MA 02110 | Cmo,Svp,Head-Res&Drug | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Disposition | 2024-02-12 | 38,618 | $15.24 | 340,484 | No | 4 | S | Direct | |
| Class A Common Stock | Acquisiton | 2024-02-12 | 54,427 | $0.00 | 394,911 | No | 4 | A | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | A | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Class A Common Stock | Performance-based Restricted Stock Unit | Acquisiton | 2024-02-12 | 27,214 | $0.00 | 27,214 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 27,214 | 2027-02-28 | No | 4 | A | Direct |
Footnotes
- The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units and performance-based restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.85 to $15.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.
- Each performance-based restricted stock unit (PSU) represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs vest upon the Issuer's Class A Common Stock achieving a specified price per share.
Billionaire Hedge Funds
